Syngene International has acquired its first US biologics facility from Emergent BioSolutions for $36.5 million.
The Baltimore site boosts Syngene’s single-use bioreactor capacity to 50,000L, supporting human and animal health markets.
The $50 million investment enhances US biologics manufacturing, with operations set for H2 2025, strengthening pharma and biotech services.
The Baltimore site boosts Syngene’s single-use bioreactor capacity to 50,000L, supporting human and animal health markets.
The $50 million investment enhances US biologics manufacturing, with operations set for H2 2025, strengthening pharma and biotech services.
